Survival of medulloblastoma g3 cannot be determined, and the exact survival time is related to the status of the disease, treatment plan, and post-treatment care. 1. Group 3 (g3) medulloblastoma accounts for 25% of all medulloblastomas and has a particularly poor prognosis. The 5-year overall survival rate is only 58% in childhood, and is even worse in infants under 3 years of age who do not receive radiation therapy, with a 5-year overall survival rate of only 45%. 2. Group 3 medulloblastoma has the poorest prognosis among medulloblastomas. Medulloblastomas are prone to metastasis, with meningeal metastasis occurring in 40% to 45% of cases, at which point there are few effective treatments and survival is compromised. 3. The prognosis is even worse when there are genetic events, such as 17q ectopic and MYC amplification, and the 5-year overall survival rate is only 20%. Group3 medulloblastoma suggests timely consultation, active treatment, reducing the adverse effects of the disease, prolonging life expectancy, maintaining a good state of mind, and establishing confidence in treatment.